MedPath
HSA Approval

VALSARTAN HCT SANDOZ FILM-COATED TABLET 160MG/25MG

SIN16127P

VALSARTAN HCT SANDOZ FILM-COATED TABLET 160MG/25MG

VALSARTAN HCT SANDOZ FILM-COATED TABLET 160MG/25MG

March 22, 2021

NOVARTIS (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

C09DA03

valsartan and diuretics

Manufacturer Information

NOVARTIS (SINGAPORE) PTE LTD

Novartis Farma S.p.A

Active Ingredients

HYDROCHLOROTHIAZIDE

25 mg

Hydrochlorothiazide

VALSARTAN

160 mg

Valsartan

Documents

Package Inserts

Valsartan HCT Sandoz Film-Coated Tablets PI.pdf

Approved: April 6, 2023

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

VALSARTAN HCT SANDOZ FILM-COATED TABLET 160MG/25MG - HSA Approval | MedPath